Comparing the Efficacy and Safety of Anti-CGRP Monoclonal Antibodies Versus Topiramate for Migraine Prophylaxis: Six-Month, Real-World, Intention-to-Treat Retrospective Evidence from the GRASP Study Group.
Saved in:
| Title: | Comparing the Efficacy and Safety of Anti-CGRP Monoclonal Antibodies Versus Topiramate for Migraine Prophylaxis: Six-Month, Real-World, Intention-to-Treat Retrospective Evidence from the GRASP Study Group. |
|---|---|
| Authors: | Vikelis, Michail1 (AUTHOR) mvikelis@headaches.gr, Rikos, Dimitrios2 (AUTHOR), Argyriou, Andreas A.3 (AUTHOR), Soldatos, Panagiotis4 (AUTHOR), Tsironis, Christos5 (AUTHOR), Giakoumakis, Emmanouil6 (AUTHOR), Xiromerisiou, Georgia7 (AUTHOR), Chondrogianni, Maria8 (AUTHOR), Foska, Aikaterini8,9 (AUTHOR), Koutsokera, Maria9,10 (AUTHOR), Notas, Konstantinos10,11 (AUTHOR), Mavraki, Eleni11,12 (AUTHOR), Dermitzakis, Emmanouil V.1,12 (AUTHOR) |
| Source: | Neurology International. Apr2026, Vol. 18 Issue 4, p67. 14p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 20358377 |
|---|---|
| DOI: | 10.3390/neurolint18040067 |
